India’s first intranasal Covid vaccine by Bharat Biotech received approval from the Drug Controller General of India (DCGI) for primary immunization against the injection for people above the age of 18. It is India’s first nasal vaccine for COVID-19. The Union Minister of Health and Family Welfare Mansukh Mandaviya termed the vaccine a ‘Big Boost’ to India’s fight against COVID-19.
Bank Maha Pack includes Live Batches, Test Series, Video Lectures & eBooks
Bharat Biotech International Limited (BBIL), is a global leader in vaccine innovation and developer of vaccines for infectious diseases. The BBIL announced that the development of the Intranasal COVID vaccine (BBV154), has been approved for restricted use in an emergency. The iNCOVACC, is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine was evaluated in phases I, II, and III, clinical trials with successful results. The vaccine was formulated to allow Intranasal delivery through nasal drops. It is designed to be cost-effective in low and middle-income countries.
India and the United Arab Emirates continue to strengthen their defence partnership with the conduct…
Jharkhand has taken a pioneering step in labour reforms with the approval of the Jharkhand…
Rivers in India are full of life and support many kinds of freshwater fish. Some…
Pulitzer Prize winning journalist Peter Arnett, one of the most influential war correspondents of the…
India and Oman have signed a Comprehensive Economic Partnership Agreement (CEPA), marking a major milestone…
China is one of the oldest countries in the world, with a history that goes…